ALLN

A 10 mM solution of ALLN (Cat. No. 208719) in anhydrous DMSO. Inhibitor of calpain I (K_i = 190 nM), calpain II (K_i = 220 nM), cathepsin B (K_i = 150 nM), and cathepsin L (K_i = 0.5 nM). Inhibits neutral cysteine proteases and proteasome (K_i = 6 µM). Protects against neuronal damage caused by hypoxia and ischemia. Inhibits apoptosis in thymocytes and metamyelocytes. Inhibits cell cycle progression at the G₁/S border and metaphase/anaphase in CHO cells by inhibiting cyclin B degradation. Also prevents nitric oxide production by activated macrophages by interfering with transcription of the inducible nitric oxide synthase gene. Inhibits the proteolysis of IkB-α and IkB-β by the ubiquitin-proteasome complex.

Cell permeable: yes

Primary Target
calpain 1

Product does not compete with ATP.

Reversible: no

Target K_i: 190 nM, 220 nM, 150 nM, 500 pM, against calpain I, calpain II, cathepsin B, and cathepsin L, respectively

Packaged under inert gas

Toxicity: Flammable (J)

A 10 mM (5 mg/1.30 ml) solution of ALLN (Cat. No. 208719) in DMSO.

Following initial thaw, aliquot and freeze (-20°C).

Milligan, S.A., et al. 1996. Arch. Biochem. Biophys.335, 388.
Griscavage, J.M., et al. 1995. Biochem. Biophys. Res. Commun.215, 721.
Squier, M.K., et al. 1994. J. Cell Physiol.159, 229.
Rami, J., and Kreiglstein, J. 1993. Brain Res.609, 67.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany